Corcept Therapeutics (CORT) Reaches $17.96 After 9.00% Up Move; Mainsource Financial Group Has 1.92 Sentiment

November 14, 2017 - By Peter Erickson

The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) is a huge mover today! About 885,822 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since November 14, 2016 and is uptrending. It has outperformed by 108.11% the S&P500.The move comes after 5 months positive chart setup for the $2.08B company. It was reported on Nov, 14 by Barchart.com. We have $19.58 PT which if reached, will make NASDAQ:CORT worth $187.20 million more.

MainSource Financial Group, Inc. is a bank holding company. The company has market cap of $930.69 million. The Firm operates a banking subsidiary, MainSource Bank , an Indiana state-chartered bank. It has a 20.48 P/E ratio. Through the Bank, the Company offers a range of financial services, including accepting time and transaction deposits; making consumer, commercial, agribusiness and real estate mortgage loans; renting safe deposit facilities; providing personal and corporate trust services, and providing other corporate services, such as letters of credit and repurchase agreements.

Corcept Therapeutics Incorporated is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company has market cap of $2.08 billion. The Firm is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor . It has a 63.39 P/E ratio. As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on March, 5. They expect $0.19 earnings per share, up 375.00% or $0.15 from last year’s $0.04 per share. CORT’s profit will be $22.00M for 23.63 P/E if the $0.19 EPS becomes a reality. After $0.11 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 72.73% EPS growth.

Investors sentiment increased to 2.43 in 2017 Q2. Its up 1.35, from 1.08 in 2017Q1. It is positive, as 11 investors sold Corcept Therapeutics Incorporated shares while 29 reduced holdings. 36 funds opened positions while 61 raised stakes. 67.64 million shares or 12.48% more from 60.14 million shares in 2017Q1 were reported. Los Angeles Capital Management & Equity Rech holds 0% or 15,589 shares in its portfolio. Moreover, Strs Ohio has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 72,900 shares. Schroder Investment Group Inc Incorporated holds 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 22,800 shares. First Quadrant L P Ca has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). California State Teachers Retirement System reported 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Bnp Paribas Arbitrage Sa stated it has 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Peak6 Investments Limited Partnership stated it has 800 shares. Catalyst Capital Advsrs Ltd Co has invested 0.03% in Corcept Therapeutics Incorporated (NASDAQ:CORT). 40,000 are held by Cambridge Trust. Timpani Capital Mngmt Lc invested in 0.55% or 125,788 shares. Buckingham Asset Mgmt Limited Liability stated it has 20,000 shares. Sei Invests stated it has 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Tfs Lc, a Pennsylvania-based fund reported 10,692 shares. Swiss Commercial Bank accumulated 138,700 shares. Principal Gp Inc reported 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics has $25.0 highest and $14 lowest target. $20.75’s average target is 15.53% above currents $17.96 stock price. Corcept Therapeutics had 7 analyst reports since February 2, 2017 according to SRatingsIntel. The rating was initiated by Ladenburg Thalmann with “Buy” on Thursday, February 2. On Wednesday, October 11 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Friday, November 3 by Stifel Nicolaus. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Piper Jaffray on Friday, September 8. The company was maintained on Thursday, August 24 by Piper Jaffray.

Analysts await MainSource Financial Group Inc. (NASDAQ:MSFG) to report earnings on January, 24. They expect $0.56 EPS, up 12.00% or $0.06 from last year’s $0.5 per share. MSFG’s profit will be $14.39M for 16.17 P/E if the $0.56 EPS becomes a reality. After $0.54 actual EPS reported by MainSource Financial Group Inc. for the previous quarter, Wall Street now forecasts 3.70% EPS growth.

Jacobs Asset Management Llc holds 3.18% of its portfolio in MainSource Financial Group Inc. for 469,078 shares. Hilton Capital Management Llc owns 445,993 shares or 2.78% of their US portfolio. Moreover, Pl Capital Advisors Llc has 2.04% invested in the company for 231,616 shares. The Texas-based Hillcrest Asset Management Llc has invested 1.35% in the stock. Heartland Advisors Inc, a Wisconsin-based fund reported 500,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com